US 12,351,604 B2
Fusion protein and use thereof
Lu Lu, Shanghai (CN); Shibo Jiang, Shanghai (CN); Zezhong Liu, Shanghai (CN); Jie Zhou, Shanghai (CN); Qian Wang, Shanghai (CN); Xia Yang, Shanxi (CN); and Zhenrui He, Shanxi (CN)
Assigned to SHANXI JINBO BIO-PHARMACEUTICAL CO., LTD., Shanxi (CN); and FUDAN UNIVERSITY, Shanghai (CN)
Appl. No. 18/865,515
Filed by SHANXI JINBO BIO-PHARMACEUTICAL CO., LTD., Shanxi (CN); and FUDAN UNIVERSITY, Shanghai (CN)
PCT Filed May 15, 2023, PCT No. PCT/CN2023/094186
§ 371(c)(1), (2) Date Nov. 13, 2024,
PCT Pub. No. WO2023/217286, PCT Pub. Date Nov. 16, 2023.
Claims priority of application No. 202210522162.6 (CN), filed on May 13, 2022.
Prior Publication US 2025/0163107 A1, May 22, 2025
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61K 39/145 (2006.01); A61K 39/215 (2006.01); A61P 31/14 (2006.01); A61P 31/16 (2006.01); C07K 14/005 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/145 (2013.01); A61K 39/215 (2013.01); A61P 31/14 (2018.01); A61P 31/16 (2018.01); C07K 2319/00 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01)] 13 Claims
 
1. A fusion protein comprising a trimerization region and an immunogenicity region linked by a linker, wherein the trimerization region comprises one or more repeating units as set forth in SEQ ID NO. 1; the immunogenicity region is an immunogenic protein of a pathogen, for example selected from the group consisting of a coronavirus RBD region, a HIV membrane protein or an influenza virus hemagglutinin protein and their immunogenic fragments, preferably the influenza virus hemagglutinin protein is H1N1 HA1 protein.